In class we have discussed a number of pharmacogenomic studies as well as the genes that we might examine in such cases. Asthma is a condition that effects millions of people, with increased diagnosis of asthma among a number of populations, including children. For asthma there are a number of approaches, some of which are based on the steroids and hormones that we discussed in class. Many of these treatments have pharmacogenomic indicators, and the number of these biomarkers have been growing.
This paper examines the process of making decisions based on pharmacogenomic data. It also serves as a nice review of the approaches to astma treatment. The process is nicely summed up in figure 3:For your response to this paper I want you to choose one of the “Gene polymorphisms and mutations (Pharmacogenetics)” listed at the bottom of this chart. Then choose one of the classes of therapy that go with that gene polymorphism. For instance you might choose “beta 2 agonists” and “ADRbeta 2 R16G(R)”. Next, find a reference that ties these two items together, I suggest that you use OMIM, search with the gene polymorphism listed.
For your response I want you to provide the literature reference that supports the connection listed in the paper, and a summarry of the connection. For my “beta 2 agonists” and “ADRbeta 2 R16G(R)” example you can find the allele variants and references here.